ClearPoint Neuro reports record Q1 revenue $8.5M, consumables up 104% YoY

ClearPoint Neuro, Inc.

2025-Q1 EPS reported -$0.22 revenue$8,485,000

Q1 revenue $8.5M (record), up 11% YoY; consumable product revenue grew 104% to $5.5M.
Neurosurgery navigation therapy revenue up 70% to $3.3M; biologics & drug delivery revenue up 9% to $4.7M.
Gross margin 60% (vs 59%); opEx up 29% to $11.3M on higher R&D and headcount.
Cash $12.4M at Mar 31 (down from $20.1M Dec 2024); credit facility secured with Oberland Capital.
FY 2025 revenue guidance reaffirmed at $36M-$41M; FDA clearance for ClearPoint 3.0 software.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.